Claritev Corporation (CTEV) Company Overview

What does Claritev Corporation do?

Claritev Corporation is a U.S. healthcare technology, data and insights company listed on the New York Stock Exchange under ticker CTEV. It does not insure patients, deliver care or pay claims. Instead, it operates in the transaction and information layer between health plans, administrators, employers and providers. Its systems analyze claims, recommend or negotiate payment amounts, provide network access, identify payment errors and turn healthcare data into decisions.

The footprint is broader than a preferred-provider network. Claritev's official solution overview groups the portfolio into Claims Intelligence, Network, Payment and Revenue Integrity, Data and Analytics, and Professional Services. Across those offerings, the purpose is to reduce medical spending, improve payment accuracy and make pricing clearer.

Who are the customers and end users?

Direct customers are typically commercial and government payers, administrative-services-only carriers, third-party administrators, property-and-casualty claims organizations and other claims-processing intermediaries. The ultimate beneficiaries are employers, plan sponsors, health plan members and providers. Claritev estimated that its solutions served more than 100,000 self-insured employers or plan sponsors in 2025. That matters because the company can reach many end clients through a relatively small number of deeply integrated payer relationships.

How does Claritev make money?

Claritev earns revenue through three principal contract structures. Percentage-of-savings, or PSAV, fees link compensation to medical-cost reductions identified or achieved. Per-employee or per-member-per-month fees create recurring revenue for network access, reference-based pricing bundles and data products. Other arrangements include subscriptions, licenses, implementation work, per-claim fees and project-based services. The 2025 Form 10-K shows that PSAV remained the dominant model at 84.0% of full-year revenue, versus 9.3% for PEPM and 6.7% for other contract types.

Which solution line generates the most revenue?

Claims Intelligence uses negotiation, reference-based pricing and products such as Data iSight to reduce out-of-network claim costs. Network Solutions monetizes access to contracted providers and network-management services. Payment and Revenue Integrity detects incorrect payments, coding issues and underpaid premiums. Data and Analytics is strategically important but is still reported within Claims Intelligence until it becomes more material.

What do Claritev's latest results show?

The quarter ended March 31, 2026 showed continued revenue recovery but also the central financial tension in the model: strong adjusted EBITDA coexists with GAAP losses, high interest expense and negative free cash flow. Claritev's Q1 2026 earnings release reported revenue of $244.7 million, up 5.8% year over year, and adjusted EBITDA of $146.9 million, up 3.4%. The adjusted EBITDA margin was 60.0%, down from 61.4% in Q1 2025.

Where did growth come from?

Claims Intelligence revenue increased 8.4% to $166.3 million, primarily because of higher Data iSight revenue, partly offset by lower surprise-billing revenue associated with client and program attrition. Network Solutions increased 1.2% to $47.5 million. Payment and Revenue Integrity was nearly flat at $30.9 million. This mix is important: almost all of the $13.3 million year-over-year revenue increase came from Claims Intelligence, so the growth story was not yet evenly distributed across the portfolio.

Which turning points shaped Claritev's current strategy?

Claritev's current position reflects its provider-network history, ownership transitions, acquisitions and recent repositioning as a broader healthcare data platform.

1. 1980
   The business was founded, beginning the decades-long accumulation of claims data, payer workflows and provider relationships that management now presents as a core asset.
2. 2001
   The nationwide Primary PPO Network first received NCQA accreditation, reinforcing quality credentials and the network's usefulness to payer clients.
3. 2016
   Hellman & Friedman-backed ownership acquired the company, contributing to the capital structure and sponsor influence that remained visible after the later public listing.
4. 2020
   The company became publicly traded through a business combination with Churchill Capital Corp III, creating access to public capital but leaving a highly leveraged enterprise.
5. 2023
   The $160.1 million Benefits Science Technologies acquisition added advanced data and analytics capabilities, supporting expansion beyond traditional network and repricing services.
6. 2024-2025
   New leadership launched Vision 2030, completed a 1-for-40 reverse stock split, refinanced debt, and changed the corporate name from MultiPlan to Claritev with the CTEV ticker.
7. 2026
   Investor Day framed “The Way Up”: expand horizontal products into payer, employer, provider, public-sector, channel-partner and international verticals while completing a cloud and digital transformation.

What changed with Vision 2030?

Vision 2030 is intended to shift Claritev from a business perceived mainly as out-of-network cost management into a technology and insights platform serving more of the healthcare lifecycle. The March 2026 Investor Day materials set long-range goals of roughly $1.1 billion of revenue in 2028 and $1.3 billion in 2030, with adjusted EBITDA targets of about $675 million and $800 million. Those are management targets, not guaranteed outcomes, but they clarify the intended strategic direction: more vertical markets, more data products, more services and eventually stronger levered free cash flow.

What gives Claritev a competitive advantage?

Claritev's advantage is the interaction of scale, historical claims data, payer-specific rules, provider relationships, workflow integration and regulatory experience. Management cites roughly 400,000 custom business rules, more than 750 payer relationships, over 45 years of claims flow, more than $500 million invested in research and development over five years, and provider acceptance above 90%.

Who are Claritev's main competitors?

Competition varies by product. Claims-intelligence rivals include Zelis, ELAP, Payer Compass and 6Degrees; network rivals include First Health, TRPN, Zelis and payer-owned networks. Payment-integrity competition includes Optum, Conduent and Cotiviti, while data and analytics brings Milliman, Merative, Artemis, HDMS and Gradient AI.

How financially strong is Claritev?

Operating profitability is high on an adjusted EBITDA basis, but the capital structure is the defining constraint. At March 31, 2026, Claritev reported $4.6 billion of long-term debt before discounts and only $21.3 million of unrestricted cash. It also had $125.0 million drawn on the 2025 revolving credit facility and $218.6 million of remaining availability after letters of credit. The weighted average cash interest rate was 6.88%.

Why does cash conversion lag adjusted EBITDA?

In FY2025, operating cash flow was $117.3 million and purchases of property and equipment were $129.6 million, producing negative free cash flow of $12.3 million. In Q1 2026, operating cash use was $45.8 million and capital expenditures were $46.8 million, producing negative free cash flow of $92.5 million. Working-capital timing, cash interest, transformation spending and internally developed software all reduce the cash available to equity holders.

Who owns Claritev stock, and why does governance matter?

Claritev has one publicly traded Class A common-stock base rather than a founder-controlled dual-class structure, but ownership is unusually concentrated among financial sponsors and institutional investors. The 2026 proxy statement reported 16.97 million shares outstanding as of March 6, 2026. Hellman & Friedman investors held 22.9%, Ares Management 11.0%, Saudi Arabia's Public Investment Fund 9.1%, Arini Capital Management 8.9% and GIC 7.3%.

How are management incentives aligned?

Travis Dalton serves as chairman, president and chief executive officer. The board has a lead independent director and Audit, Compensation, Nominating and Corporate Governance, and Risk committees. Annual incentives use financial and strategic measures, while long-term awards include equity and cash-settled restricted units. Researchers should watch dilution and whether incentives emphasize free cash flow and leverage reduction.

What opportunities and risks could change Claritev's outlook?

The opportunity case rests on using existing data, distribution and provider relationships in more markets. Claritev is targeting providers, government, employers, brokers, channel partners, international customers and professional services. Management reported more than $67 million of new annual contract value in 2025 and set a 2026 target of $80 million to $100 million; bookings can take two to four quarters to convert into revenue.

Which risks are most material?

Client concentration is immediate: two clients represented 29.2% and 10.4% of FY2025 revenue. A contract loss, pricing reset or shift in claims volume at either could materially affect earnings. Regulation is another core risk. Claritev's surprise-billing services, independent-dispute-resolution fees, provider contracts and access to protected health information expose it to changing federal and state requirements, including the No Surprises Act, HIPAA, privacy laws and government-program rules.

Legal and enforcement risk is not theoretical. In May 2026, Claritev disclosed that it had received a confidential grand-jury subpoena from the Department of Justice Antitrust Division in August 2024 regarding health insurance, while stating that it had not been informed it was a target and was cooperating. The company's May 18, 2026 Form 8-K should be read as a live monitoring item rather than proof of an adverse outcome.

Which KPIs matter most for Claritev?

Claritev should not be evaluated with a single revenue-growth or EBITDA multiple. Claims volume, savings economics, retention, bookings, provider acceptance, technology investment and debt service all matter. A KPI system helps separate operating improvement from accounting presentation.

How should margin quality be judged?

The large gap between adjusted EBITDA margin and GAAP operating margin reflects amortization of acquired intangibles, depreciation, stock compensation and transformation costs. The negative Q1 free-cash-flow margin is shown as the magnitude of the cash deficit relative to revenue, not as a positive margin. Analysts should reconcile these layers rather than treating any one of them as the complete earnings picture.

Why does Claritev's business model matter for valuation?

A Claritev valuation is unusually sensitive to the relationship between enterprise value and debt. The operating business can appear inexpensive on an adjusted EBITDA multiple while the common equity remains risky because creditors have a large prior claim on enterprise value. A DCF therefore needs explicit assumptions for cash interest, PIK accretion, capital expenditures, working capital and debt reduction rather than a simple EBITDA-to-free-cash-flow shortcut.

Which variables should a DCF model emphasize?

Management's long-range presentation targets about $75 million of levered free cash flow in 2028 and $225 million in 2030. The upside mechanism is better cash conversion and debt reduction; without it, the debt overhang remains dominant.

What is the key takeaway from Claritev analysis?

Claritev combines a large independent provider network, decades of claims data and embedded payer workflows. Its products address medical-cost inflation, opaque pricing, payment error and payer-provider friction. The return to growth in 2025 and 5.8% growth in Q1 2026 suggest that Data iSight, network expansion and new verticals are creating momentum.

Claritev entered 2026 with a highly leveraged balance sheet, large interest expense, negative book equity and weak near-term free-cash-flow conversion. Two clients represented 39.6% of FY2025 revenue, while antitrust, privacy, surprise-billing and reimbursement rules create continuing regulatory exposure. The strategic transformation also requires significant capital spending before its promised efficiency benefits are fully visible.